新型喹诺酮类药物 UB-8902 对氧氟沙星耐药分离株的活性。
Activity of a Novel Quinolone, UB-8902, Against Ofloxacin-Resistant Isolates.
机构信息
Microbiology Department, CDB, Hospital Clinic-Barcelona Institute of Global Health (ISGlobal), University of Barcelona, Barcelona, Spain.
Cenavisa Plc Laboratories, Reus, Tarragona, Spain.
出版信息
Microb Drug Resist. 2020 Sep;26(9):1019-1022. doi: 10.1089/mdr.2019.0367. Epub 2020 Mar 10.
The main objective of this study was to compare activities of a novel fluoroquinolone (FQ), UB-8902, with ofloxacin (OFX), levofloxacin (LFX), and moxifloxacin (MOX) against isolates. Eleven OFX-resistant and 11 drug-susceptible clinical isolates were studied. Individual minimum inhibitory concentrations of OFX, LFX, MOX, and UB-8902 were determined using Middlebrook 7H11 agar. The concentrations studied ranged from 0.125 to 128 μg/mL in twofold dilutions. UB-8902 was more active than LFX and similar to MOX for OFX-resistant isolates. In addition, UB-8902 and MOX showed equal activity against drug-susceptible isolates, both being more active than OFX and LFX. In conclusion, the new FQ, UB-8902, showed good activity against OFX-resistant isolates. Moreover, it showed better activity than OFX and LFX and was equivalent to MOX against FQ-susceptible clinical isolates. UB-8902 can be considered as a drug with potential antituberculous activity, similar to MOX.
本研究的主要目的是比较新型氟喹诺酮（FQ）UB-8902 与氧氟沙星（OFX）、左氧氟沙星（LFX）和莫西沙星（MOX）对分离株的活性。研究了 11 株 OFX 耐药和 11 株药物敏感的临床分离株。采用 Middlebrook 7H11 琼脂测定 OFX、LFX、MOX 和 UB-8902 的个体最小抑菌浓度。研究的浓度范围为 0.125 至 128μg/ml，以两倍稀释。UB-8902 对 OFX 耐药分离株的活性优于 LFX 且与 MOX 相似。此外，UB-8902 和 MOX 对药敏分离株的活性相同，均优于 OFX 和 LFX。总之，新型 FQ UB-8902 对 OFX 耐药分离株显示出良好的活性。此外，它的活性优于 OFX 和 LFX，与 MOX 对 FQ 敏感的临床分离株相当。UB-8902 可被视为一种具有潜在抗结核活性的药物，类似于 MOX。
Zotero 插件